1

2
Beigelman Leonid, Seiwert Scott D, Blatt Lawrence M, Andrews Steven, Haas Julia: Compounds and methods for inhibiting hepatitis c viral replication. Intermune, Array Biopharma, Beigelman Leonid, Seiwert Scott D, Blatt Lawrence M, Andrews Steven, Haas Julia, MALLON Joseph J, April 19, 2007: WO/2007/044893 (56 worldwide citation)

Macrocyclic compounds having the structures described herein arc useful for inhibiting replication of the hepatitis C virus (HCV). In preferred embodiments, the compounds are active against both the NS3 protease and the NS3 helicase of HCV. Formulae (I), (II), (III), (IV) and (V).


3
BUCKMAN Brad, NICHOLAS John B, SEREBRYANY Vladimir, SEIWERT Scott D: Nouveaux inhibiteurs de la réplication du virus de lhépatite c, Novel inhibitors of hepatitis c virus replication. Intermune, BUCKMAN Brad, NICHOLAS John B, SEREBRYANY Vladimir, SEIWERT Scott D, HART Daniel, November 24, 2011: WO/2011/146401 (36 worldwide citation)

The embodiments provide compounds of the general Formulae (VI), (VII), (VIII), (IX), (X), (XI), (XII), (XIII), (XIV), and (XV) as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treati ...


4
BUCKMAN Brad, NICHOLAS John B, SEREBRYANY Vladimir, SEIWERT Scott D: NOUVEAUX INHIBITEURS DE LA RÉPLICATION DU VIRUS DE LHÉPATITE C, NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION. INTERMUNE, BUCKMAN Brad, NICHOLAS John B, SEREBRYANY Vladimir, SEIWERT Scott D, MALLON Joseph J, June 28, 2012: WO/2012/087976 (16 worldwide citation)

The embodiments provide compounds of the general Formulae XV, XVI, XVII and XVIII as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods ...


5
Blatt Lawrence M, Seiwert Scott D, Ozes Osman N: Combination therapy for proliferative disorders. Intermune, Blatt Lawrence M, Seiwert Scott D, Ozes Osman N, BORDEN Paula A, December 9, 2004: WO/2004/105684 (16 worldwide citation)

The present invention provides methods of treating proliferative disorders, including angiogenesis-mediated disorders, cancer, and fibrotic disorders. In some embodiments, the methods involve administering a Type II interferon receptor agonist and a Type I interferon receptor agonist. In other embod ...


6
Ozes Osman N, Blatt Lawrence M, Seiwert Scott D: Use of pirfenidone in therapeutic regimens. Intermune, Ozes Osman N, Blatt Lawrence M, Seiwert Scott D, BORDEN Paula A, May 6, 2005: WO/2005/040758 (14 worldwide citation)

The present invention provides methods for treating a disorder, and methods for inhibiting a stress-activated protein kinase (SAPK) in a cell in an individual, the methods generally involving administering to an individual in need thereof an effective amount of pirfenidone or a pirfenidone analog; c ...


7
Blatt Lawrence M, Seiwert Scott D, Beigelman Leonid, Radhakrishnan Ramachandran: Pyridone derivatives for modulating stress-activated protein kinase system. Intermune, Blatt Lawrence M, Seiwert Scott D, Beigelman Leonid, Radhakrishnan Ramachandran, RIN LAURES Lily, November 16, 2006: WO/2006/122154 (12 worldwide citation)

Disclosed are methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of at least one p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentag ...


8
Seiwert Scott D, Kossen Karl, Serebryany Vladimir: Method of modulating stress-activated protein kinase system. Intermune, Seiwert Scott D, Kossen Karl, Serebryany Vladimir, LILY RIN LAURES, May 31, 2007: WO/2007/062167 (11 worldwide citation)

It has now been discovered that a high therapeutic effect in treating various disorders associated with enhanced activity of kinase p38 may be achieved by using a potent p38? kinase inhibitor compound which also has inhibitory activity against p38?. Furthermore, reducing the activities of both kinas ...


9
BUCKMAN Brad, NICHOLAS John B, SEREBRYANY Vladimir, SEIWERT Scott D: INHIBITEURS PROLINE SUBSTITUÉE DE RÉPLICATION DU VIRUS DE LHÉPATITE C, SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION. INTERMUNE, BUCKMAN Brad, NICHOLAS John B, SEREBRYANY Vladimir, SEIWERT Scott D, MILLER Kimberly J, March 29, 2012: WO/2012/040242 (10 worldwide citation)

The embodiments provide compounds of the general Formulae I, la, II,IIa,III, IIIa, Illb, IV, IVa, IVb, V, Va, Vb, VI, VIa, VIb, and VIc, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods ...


10
BUCKMAN Brad, NICHOLAS John B, SEREBRYANY Vladimir, SEIWERT Scott D: NOUVEAUX INHIBITEURS DE LA RÉPLICATION DU VIRUS DE LHÉPATITE C, NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION. INTERMUNE, BUCKMAN Brad, NICHOLAS John B, SEREBRYANY Vladimir, SEIWERT Scott D, MILLER Kimberly J, March 22, 2012: WO/2012/037259 (9 worldwide citation)

The invention relates to macrocyclic compounds of Formula e I. (in which the variables are as defined herein) for use in the treatment of hepatitis C virus. Therapeutic methods, medicaments and dosage forms related thereto are also disclosed.